We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · February 20, 2021

Cobimetinib + Chemotherapy ± Atezolizumab as First-Line Treatment for Locally Advanced or Metastatic Triple-Negative Breast Cancer

Annals of Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
A Phase II Randomized Trial of Cobimetinib Plus Chemotherapy, With or Without Atezolizumab, as First-Line Treatment for Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (COLET): Primary Analysis
Ann. Oncol 2021 Feb 01;[EPub Ahead of Print], A Brufsky, SB Kim, Ž Zvirbule, A Eniu, J Mebis, JH Sohn, M Wongchenko, S Chohan, R Amin, Y Yan, V McNally, D Miles, S Loi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading